25% Investment Upside - Positive Cancer Treatment News is Driving This Stock

Quick investment opportunity based on recent news. Trading Overview Entry Price should be around $2.00 Target Price should be around $2.50 Set a stop loss of 5% ($1.90) Recent news about OncoCyte's drug Determarx shows signs to help battle lung cancer. Trials will start with patients this quarter and the company is presenting its findings at the North American Conference for Lung Cancer.

back

25% Investment Upside - Positive Cancer Treatment News is Driving This Stock

Oct 14, 2020

bullish

fundamentals Analysis

[< 1 min Read]

Quick investment opportunity based on recent news. Trading Overview Entry Price should be around $2.00 Target Price should be around $2.50 Set a stop loss of 5% ($1.90) Recent news about OncoCyte's drug Determarx shows signs to help battle lung cancer. Trials will start with patients this quarter and the company is presenting its findings at the North American Conference for Lung Cancer.
page loading card

OCX

OncoCyte Corporation

0.85

0
0.00%

Return

-
Position Return %
0.00
Position Return
1.46
Price When Posted

Metrics

2.50
Target Price
6/ 10
Confidence
< 1 Week
Timeframe
catalyst icon
Earnings Per Share
catalyst icon
Financials
catalyst icon
Management
catalyst icon
Price to Earnings Ratio
catalyst icon
Dividend
catalyst icon
Other Catalyst

Access the latest tools and discussion channels with an account

reddit-sentiment

Reddit Sentiment
Analysis

portfolio-balancer

Portfolio Balancer
with brokerages

sec-dashboard

SEC Dashboard
with NLP

aiodd-ad
next